Akebia Therapeutics Inc. (NASDAQ:AKBA)’s share price was up 2.5% during trading on Monday . The stock traded as high as $8.35 and last traded at $8.15, with a volume of 96,662 shares trading hands. The stock had previously closed at $7.95.

A number of equities research analysts have recently issued reports on AKBA shares. Zacks Investment Research raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, July 18th. Credit Suisse Group AG reissued a “hold” rating on shares of Akebia Therapeutics in a research report on Tuesday, July 12th. JMP Securities reissued a “market perform” rating and issued a $16.00 target price on shares of Akebia Therapeutics in a research report on Thursday, August 11th. HC Wainwright reissued a “buy” rating on shares of Akebia Therapeutics in a research report on Monday, May 16th. Finally, Brean Capital reissued a “buy” rating on shares of Akebia Therapeutics in a research report on Sunday, May 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $15.75.

The stock’s market capitalization is $150.43 million. The firm has a 50 day moving average of $8.42 and a 200-day moving average of $8.44.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.38. Equities analysts expect that Akebia Therapeutics Inc. will post ($3.73) EPS for the current fiscal year.

A hedge fund recently raised its stake in Akebia Therapeutics stock. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Akebia Therapeutics Inc. (NASDAQ:AKBA) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 97,925 shares of the biopharmaceutical company’s stock after buying an additional 8,500 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.54% of Akebia Therapeutics worth $1,265,000 at the end of the most recent quarter.

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.